Pramodini Medicare proposes Rs 6.12 crore Mahathi stake deal
Key highlights
- Pramodini Medicare agreed on November 13, 2026, to acquire 51% of Mahathi Imaging through 1,020 equity shares.
- The indicative cash consideration is Rs 6.12 crore, equal to Rs 60,000 per Mahathi Imaging share.
- Mahathi Imaging reported turnover of Rs 5.4856 crore in 2025-26, versus Rs 5.2144 crore in 2024-25.
- The transaction is targeted for completion within 90 days of letter acceptance, with a possible 30-day extension.
powered by IRIS

Pramodini Medicare Limited agreed on November 13, 2026, to acquire 51% of Mahathi Imaging and Diagnostics Private Limited for indicative cash consideration of Rs 6.12 crore. The proposed purchase covers 1,020 equity shares, but the final consideration remains subject to due diligence, an independent valuation and a Share Purchase Agreement.
Know Pramodini Medicare inside out
Results, valuation, peers and who's buying, in one view.
What has Pramodini Medicare agreed to acquire?
Pramodini Medicare has agreed to acquire 1,020 equity shares representing 51% of Mahathi Imaging, according to its November 14, 2026 disclosure under Regulation 30 of the Securities and Exchange Board of India listing regulations. Mahathi Imaging is a diagnostic imaging and diagnostic services company incorporated on November 29, 2018.
The proposed transaction involves sale shares held by selling shareholder or shareholders rather than a new issue of shares by Mahathi Imaging. Pramodini Medicare said the shares are to transfer with all attached rights and free of liens, charges, pledges and encumbrances, subject to verification during due diligence and the terms of definitive documents.
Pramodini Medicare reported that the transaction is not a related-party transaction, and that its promoter, promoter group and group companies have no interest in Mahathi Imaging. While a 51% shareholding represents control of the target's total capital, the filing does not identify the seller or sellers of the 1,020 shares.
What is the proposed price for the Mahathi Imaging stake?
Pramodini Medicare has disclosed indicative cash consideration of Rs 6.12 crore for the 1,020 Mahathi Imaging shares, or Rs 60,000 per equity share. This is an indicative price for the proposed 51% holding rather than a final purchase price.
The final consideration will be determined using a valuation report from a merchant banker or an independent valuer, Pramodini Medicare said. Final payment terms and conditions will be set out in the Share Purchase Agreement, or SPA, and may therefore differ from the announced Rs 6.12 crore indication.
Pramodini Medicare said it will disclose detailed acquisition information, including the price, on the actual date of the share purchase. The filing does not state the valuation methodology, any adjustment mechanism, or the date on which the merchant banker or independent valuer will provide the report.
What business does Mahathi Imaging operate?
Mahathi Imaging operates in diagnostic and hospital activities, with diagnostic imaging and diagnostic services identified as its business lines. It has its registered office in Tirupati, Chittor District, Andhra Pradesh, India, and was incorporated on November 29, 2018.
The filing states that Mahathi Imaging has its presence in India and does not describe operations in any other country. It also does not disclose individual imaging modalities, the number of diagnostic centres, hospital relationships, patient volumes, assets, debt or profitability for the Tirupati-based business.
Pramodini Medicare described the acquisition's object through the proposed share-transfer structure rather than through a quantified operating plan. The disclosure says the 1,020 sale shares are to be acquired with attached rights, while due diligence will verify the status of the shares and other matters before completion.
Got a follow-up? Ask IRIS
How has Mahathi Imaging's turnover changed over three years?
Mahathi Imaging reported turnover of Rs 5.4856 crore in 2025-26, compared with Rs 5.2144 crore in 2024-25 and Rs 5.5673 crore in 2023-24. The latest reported turnover was therefore Rs 27.12 lakh higher than in 2024-25 but Rs 8.17 lakh below the 2023-24 level.
The three-year comparison shows turnover first declining and then recovering. Turnover fell by Rs 35.29 lakh between 2023-24 and 2024-25, before rising by Rs 27.12 lakh in 2025-26; Pramodini Medicare's November 14, 2026 filing provides no explanation for either movement.
These disclosed numbers are turnover figures, not measures of profit, cash flow or net assets. The filing gives no margin, borrowing, capital-expenditure, customer-concentration or diagnostic-centre data, and it does not state how the eventual valuation report will assess Mahathi Imaging's 2023-24 to 2025-26 performance.
When could the proposed acquisition be completed?
Pramodini Medicare said the proposed transaction is to be completed within 90 days from the date of acceptance of the letter. The proposed acquirer may extend that period by a further 30 days at its sole discretion, creating a disclosed timetable of up to 120 days from that acceptance date.
No governmental or regulatory approvals were listed as required for the transaction. Completion nevertheless remains subject to due diligence, verification of the sale shares and definitive documentation, including the SPA that will record final consideration and payment arrangements.
The November 14, 2026 announcement does not disclose the acceptance date from which the 90-day period is calculated, nor does it provide a fixed closing date. Its stated process requires a valuation report, due diligence and definitive documents before Pramodini Medicare publishes details on the actual share-purchase date.
Conclusion
Pramodini Medicare's proposed acquisition would give it a 51% holding in Mahathi Imaging through the purchase of 1,020 shares for indicative cash consideration of Rs 6.12 crore. Mahathi Imaging reported turnover of Rs 5.4856 crore in 2025-26, up from Rs 5.2144 crore in 2024-25 but below Rs 5.5673 crore in 2023-24.
The next disclosed matters to watch are due diligence, the valuation report and execution of the SPA, which will set final consideration and payment terms. Pramodini Medicare has also said it will provide detailed acquisition information on the actual share-purchase date, while the completion period is 90 days from acceptance of the letter with a possible further 30-day extension.


